

A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study



Martin Than, Louise Cullen, Christopher M Reid, Swee Han Lim, Sally Aldous, Michael W Ardagh, W Frank Peacock, William A Parsonage, Hiu Fai Ho, Hiu Fai Ko, Ravi R Kasliwal, Manish Bansal, Sunarya Soerianata, Dayi Hu, Rongjing Ding, Qi Hua, Kang Seok-Min, Piyamitr Sritara, Ratchanee Sae-Lee, Te-Fa Chiu, Kuang-Chau Tsai, Fang-Yeh Chu, Wei-Kung Chen, Wen-Han Chang, Dylan F Flaws, Peter M George, A Mark Richards

Summary

Background Patients with chest pain contribute substantially to emergency department attendances, lengthy hospital stay, and inpatient admissions. A reliable, reproducible, and fast process to identify patients presenting with chest pain who have a low short-term risk of a major adverse cardiac event is needed to facilitate early discharge. We aimed to prospectively validate the safety of a predefined 2-h accelerated diagnostic protocol (ADP) to assess patients presenting to the emergency department with chest pain symptoms suggestive of acute coronary syndrome.

Methods This observational study was undertaken in 14 emergency departments in nine countries in the Asia-Pacific region, in patients aged 18 years and older with at least 5 min of chest pain. The ADP included use of a structured pre-test probability scoring method (Thrombolysis in Myocardial Infarction [TIMI] score), electrocardiograph, and point-of-care biomarker panel of troponin, creatine kinase MB, and myoglobin. The primary endpoint was major adverse cardiac events within 30 days after initial presentation (including initial hospital attendance). This trial is registered with the Australia-New Zealand Clinical Trials Registry, number ACTRN12609000283279.

Findings 3582 consecutive patients were recruited and completed 30-day follow-up. 421 (11·8%) patients had a major adverse cardiac event. The ADP classified 352 (9·8%) patients as low risk and potentially suitable for early discharge. A major adverse cardiac event occurred in three (0·9%) of these patients, giving the ADP a sensitivity of 99·3% (95% CI 97·9–99·8), a negative predictive value of 99·1% (97·3–99·8), and a specificity of 11·0% (10·0–12·2).

Interpretation This novel ADP identifies patients at very low risk of a short-term major adverse cardiac event who might be suitable for early discharge. Such an approach could be used to decrease the overall observation periods and admissions for chest pain. The components needed for the implementation of this strategy are widely available. The ADP has the potential to affect health-service delivery worldwide.

Funding Alere Medical (all countries), Queensland Emergency Medicine Research Foundation and National Health and Medical Research Council (Australia), Christchurch Cardio-Endocrine Research Group (New Zealand), Medquest Jaya Global (Indonesia), Science International (Hong Kong), Bio Laboratories Pte (Singapore), National Heart Foundation of New Zealand, and Progressive Group (Taiwan).

Introduction

Every year, an estimated 5–10% of presentations to emergency departments, and up to a quarter of hospital admissions are attributable to symptoms suggestive of acute coronary syndromes.¹ Patients with a missed diagnosis of acute myocardial infarction are at increased risk of a major adverse cardiac event. The need for safe discharge without a substantial risk of a major adverse cardiac event is a priority and a driver of clinician behaviour. Consequently, most patients with symptoms suggestive of acute coronary syndromes undergo lengthy assessment, either in the emergency department or as hospital inpatients, even though 75–85% of these patients ultimately do not have a final diagnosis of acute coronary syndromes.^{2–4} The assessment processes vary between institutions, with no one process being ideal.

Present recommendations are for serial sampling of cardiac troponin over at least 6 h from the onset of symptoms.^{5–7} Concerns about accuracy of patients' recall of events has led many centres to time troponin sampling from the moment of presentation to the emergency department.⁸ Prolonged assessment contributes to overcrowding in the hospital or department, physician duplication of effort, and clinical risk as patients are treated by different clinical staff.¹ Emergency department overcrowding is associated with increased costs and adverse patient outcomes, including increased mortality.⁹

A reliable, reproducible, and more timely process for the identification of chest pain presentations that have a low short-term risk of a major adverse cardiac event is needed to facilitate earlier discharge.⁴ Accelerated diagnostic

Lancet 2011; 377: 1077–84

Published Online

March 23, 2011

DOI:10.1016/S0140-

6736(11)60310-3

See [Comment](#) page 1049

Christchurch Hospital, Christchurch, New Zealand (M Than MBBS, S Aldous MBChB, Prof P M George MBBS); Royal Brisbane and Women's Hospital, Herston, QLD, Australia (L Cullen MBBS, W A Parsonage MD); Monash University, Melbourne, VIC, Australia (Prof C M Reid PhD); Singapore General Hospital, Singapore, Singapore (Prof S H Lim MBBS); University of Otago, Christchurch, New Zealand (Prof M W Ardagh PhD, Prof A M Richards MD); Cleveland Clinic Foundation, Cleveland, OH, USA (W F Peacock MD); Queen Elizabeth Hospital, Hong Kong, China (H F Ho MD, H F Ko MD); Medanta—The Medicity, Gurgaon, India (R R Kasliwal MD, M Bansal MD); National Cardiovascular Centre Harapan Kita, Jakarta, Indonesia (S Soerianata MD); People's Hospital, Beijing, China (Prof D Hu MD, R Ding MD); Xuanwu Hospital, Beijing, China (Q Hua MD); Severance Hospital, Seoul, South Korea (Prof K Seok-Min MD); Ramathibodi Hospital, Bangkok, Thailand (Prof P Sritara MD, Prof R Sae-Lee MD); Chang Gung Memorial Hospital, Keelung, Taiwan (T-F Chiu MD); Far Eastern Memorial Hospital, Taipei, Taiwan (K-C Tsai MD, F-Y Chu MD); China Medical University Hospital, Taichung, Taiwan (W-K Chen MD); MacKay Memorial Hospital, Taipei, Taiwan (W-H Chang DrPH); Queensland University of Technology, Brisbane, QLD, Australia (L Cullen); and University of

Queensland, Brisbane, Australia (D F Flaws MSc)

Correspondence to: Dr Martin Than, Department of Emergency Medicine, Canterbury District Health Board, Private Bag 4710, Christchurch, New Zealand
martinthan@xtra.co.nz

Panel 1: The TIMI score for unstable angina or non-ST elevation myocardial infarction¹⁵

- (1) Age 65 years or older
- (2) Three or more risk factors for coronary artery disease (family history of coronary artery disease, hypertension, hypercholesterolaemia, diabetes, or being a current smoker)
- (3) Use of aspirin in the past 7 days
- (4) Significant coronary stenosis (eg, previous coronary stenosis $\geq 50\%$)
- (5) Severe angina (eg, two or more angina events in past 24 h or persisting discomfort)
- (6) ST-segment deviation of 0.05 mV or more on first electrocardiograph
- (7) Increased troponin and/or creatine kinase MB on initial blood tests*

The TIMI score had to be zero for the sum of its seven parameters to be categorised as 0. TIMI=Thrombolysis In Myocardial Infarction. *Point-of-care values were used for TIMI score calculation.

protocols (ADPs), clinical decision rules, and prediction rules are terms for processes or methods intended to help clinicians to make bedside diagnostic and therapeutic decisions. They involve variables from the patient's history and examination, and often incorporate the results of diagnostic tests.⁶ ADPs for chest pain are well established but emphasise the need to assess the patient for at least 6 h after the onset of symptoms.^{6,10} Some studies have safely investigated patients with serial biomarkers during 1.5–3 h in a low-risk patient group, but have not defined a reproducible method to identify this low-risk group.¹¹

For an assessment of possible acute coronary syndromes, a maximum of 60 min is recommended for the availability of troponin results.¹² Many central laboratories have difficulty in meeting this standard. Point-of-care biomarkers represent a possible solution to meeting this target. The Thrombolysis In Myocardial Infarction (TIMI) score for unstable angina or non-ST elevation myocardial infarction is an externally validated and widely used structured risk assessment method.^{1,13,14} Its use in conjunction with serial 0–2 h biomarker testing




Figure 1: Trial profile of participant recruitment and outcomes according to ADP classification

30-day follow-up includes initial hospital attendance. Patients lost to follow-up did not have a MACE during initial hospital attendance. TIMI=Thrombolysis In Myocardial Infarction score for unstable angina or non-ST-elevation myocardial infarction. ADP=accelerated diagnostic protocol. MACE=major adverse cardiac event.

(either via central laboratory or point-of-care systems) and electrocardiograph (ECG) has not been prospectively tested. Importantly, there has been little validation of ADPs based in emergency departments outside North America, or in diverse population groups such as the Asia-Pacific population, in whom a mix of ethnic backgrounds and variations in service delivery introduce important differences.¹⁵

The ASia-Pacific Evaluation of Chest pain Trial (ASPECT) was a prospective observational validation study designed to assess whether a predefined ADP would identify patients presenting to the emergency department with chest pain, who would be at low risk of harm if they were to be discharged early.

Methods

Participants

Enrolment occurred at 14 urban emergency departments in nine countries in the Asia-Pacific region (Australia, China [including Hong Kong], India, Indonesia, New Zealand, Singapore, South Korea, Taiwan, and Thailand). Patients were included if they were at least 18 years old and had at least 5 min of chest pain (or discomfort) suggestive of acute coronary syndromes for whom the attending physician planned to investigate for these syndromes with serial biomarker tests. In accordance with American Heart Association case definitions,¹⁶ possible cardiac symptoms included acute chest; epigastric, neck, jaw, or arm pain; or discomfort or pressure without an apparent non-cardiac source. Generally, atypical symptoms (fatigue, nausea, vomiting, diaphoresis, faintness, and back pain) were not used as inclusion criteria in the absence of chest pain.

Patients were excluded if they had an ST-segment elevation acute myocardial infarction, there was a clear cause other than acute coronary syndromes for the symptoms (eg, clinical findings of pneumonia), they were unable or unwilling to provide informed consent, staff considered recruitment to be inappropriate (eg, terminal illness), they were transferred from another hospital, they were pregnant, they were recruited on previous presentation, or they were unable to be contacted after discharge. Perceived high risk was not regarded as an exclusion criterion. Recruitment included consecutive eligible cases at each site. Overall enrolment occurred between November, 2007, and July, 2010, but individual sites started and finished at different times according to local logistics. Patients were managed according to local protocols.

All data collection occurred prospectively and the data dictionary has been published previously.¹⁷ Research nursing staff collected the demographic and risk data from each patient, supervised ECG testing, and drew blood samples for biomarker testing. If a patient was unsure of an answer (eg, family history) a response of no was recorded. Patients were tracked for adverse events at 30 days from initial attendance with hospital records and

	Low risk (n=352)	High risk (n=3230)	Total
Age (years)	49.8 (9.2)	62.8 (14.0)	61.5 (14.1)
Men	220 (62.5%)	2014 (62.4%)	2234 (62.4%)
Ethnic origin			
White	190 (56.4%)	1281 (40.5%)	1471 (42.1%)
Chinese	66 (19.6%)	1108 (35.1%)	1174 (33.6%)
Korean	26 (7.7%)	194 (6.1%)	220 (6.3%)
Indonesian	10 (3.0%)	200 (6.3%)	210 (5.9%)
Indian	9 (2.7%)	122 (3.9%)	131 (3.7%)
Thai	0	70 (2.2%)	70 (2.0%)
Malay	2 (0.6%)	46 (1.5%)	48 (1.3%)
Maori	3 (0.9%)	30 (0.9%)	33 (0.9%)
Aboriginal	1 (0.3%)	8 (0.3%)	9 (0.3%)
Other	30 (8.9%)	102 (3.2%)	132 (3.7%)
Unknown	15 (4.2%)	69 (2.1%)	84 (2.3%)
Hypertension	65 (19.9%)	1921 (60.4%)	1986 (56.5%)
Dyslipidaemia	76 (24.0%)	1505 (48.3%)	1581 (46.0%)
Family history of CAD	124 (39.9%)	1196 (37.6%)	1320 (38.1%)
Smoking			
Previous	106 (32.3%)	1061 (33.2%)	1167 (33.1%)
Current	69 (21.0%)	625 (19.5%)	694 (19.7%)
Past medical history			
Angina	18 (8.6%)	1120 (44.0%)	1138 (41.3%)
CAD	4 (1.9%)	735 (28.9%)	739 (26.8%)
Acute myocardial infarction	0	625 (24.5%)	625 (22.7%)
Revascularisation	0	541 (21.3%)	541 (19.7%)
Congestive heart failure	2 (1.0%)	281 (11.0%)	283 (10.3%)
Stroke	3 (1.4%)	278 (10.9%)	281 (10.2%)
CABG	0	200 (7.8%)	200 (7.3%)
Arrhythmia	5 (2.0%)	158 (6.2%)	163 (5.9%)
Length of initial hospital attendance (h)	26.0 (9.9–37.0)	50.1 (12.6–123.3)	46.0 (12.0–120.8)

Data are mean (SD), number (%), or median (IQR). Data were missing for each category as follows: ethnic origin (84), hypertension (75), dyslipidaemia (148), family history of CAD (118), smoking (54), previous medical history (824), and time in hospital (196). ADP=accelerated diagnostic protocol. CAD=coronary artery disease. CABG=coronary artery bypass graft.

Table 1: Characteristics for low-risk (ADP negative) and high-risk (ADP positive) participants in the ASPECT study (n=3582)

telephone follow-up. Data coordination, monitoring and analysis, and source verification was done through an independent university clinical research organisation at a non-recruitment location in Australia (Centre for Clinical Research Excellence, Monash University, Melbourne). Approval from local ethics committees was obtained, and all patients provided written informed consent.

Procedures

The primary endpoint was major adverse cardiac events within 30 days after initial presentation (including initial hospital attendance). The criteria for major adverse cardiac event included any of the following: death (not clearly non-cardiac), cardiac arrest, an emergency revascularisation procedure, cardiogenic shock, ventricular arrhythmia needing intervention, high-degree atrioventricular block needing intervention,

	Number of events*	Patients (of 421) who had event type (%)	Frequency of event type (of 3582 patients in study; %)
NSTEMI	363	86.2%	10.1%
STEMI	53	12.5%	1.5%
Emergency revascularisation	32	7.6%	0.9%
Cardiovascular death	19	4.5%	0.5%
Ventricular arrhythmia	15	3.5%	0.4%
Cardiac arrest	8	1.9%	0.2%
Cardiogenic shock	7	1.7%	0.2%
High atrioventricular block	4	1.0%	0.1%

NSTEMI=non-ST-segment elevation myocardial infarction. STEMI=ST-segment myocardial infarction occurring after initial recruitment. *421 of 3582 (11.8%) patients had a total of 501 events during initial hospital attendance or 30-day follow-up.

Table 2: Frequency and type of major adverse cardiac event during initial hospital attendance or 30-day follow-up

and prevalent (ie, being the cause for the patient’s initial presentation) and incident (ie, occurring during the 30-day follow-up) acute myocardial infarction. Outcomes and investigations were reported with minimum subjectivity with predefined standardised reporting guidelines (webappendix p 1).^{16–20} The presence of a major adverse cardiac event was adjudicated independently by local cardiologists with these reporting guidelines. Cardiologists were masked to results of the index test biomarkers under investigation and derived TIMI score, but had knowledge of the clinical record, ECG, and serial troponin results from usual care.

In accordance with international guidelines, blood troponins at presentation, and then at least 6 h afterwards formed part of the reference standard to establish presence of acute myocardial infarction.^{7,16} These measurements were part of normal care and were analysed at the recruitment site central hospital laboratory. Webappendix p 2 provides a summary of the characteristics of the laboratory troponins used at each hospital site. Treating clinicians were masked to the results of the index tests, with only central laboratory troponin results used in patient management. Classification of acute myocardial infarction was based on global taskforce recommendations requiring evidence of myocardial necrosis together with evidence of myocardial ischaemia (ischaemic symptoms, ECG changes, or imaging evidence).⁷ Necrosis was diagnosed on the basis of a rising or falling pattern of the laboratory cardiac troponin concentrations, with at least one value above the 99th percentile, at a level of assay imprecision near to 10%. If the troponin concentration was greater than the reference range, but no rise or fall was recorded, other causes of a raised troponin concentration were considered by the adjudicating cardiologist. If no clear alternative cause of the troponin rise was apparent, and if the clinical presentation was suggestive of acute coronary

	MACE	No MACE	Total
ECG*			
Positive	148 (4.1%)	879 (24.5%)	1027 (28.7%)
Negative	273 (7.6%)†	2282 (63.7%)	2555 (71.3%)
Total	421 (11.8%)	3161 (88.2%)	3582 (100%)
TIMI‡			
Positive	407 (11.4%)	2606 (72.8%)	3013 (84.1%)
Negative	14 (0.4%)†	555 (15.4%)	569 (15.9%)
Total	421 (11.8%)	3161 (88.2%)	3582 (100%)
ECG and TIMI§			
Positive	413 (11.6%)	2701 (75.4%)	3114 (86.9%)
Negative	8 (0.2%)†	460 (12.8%)	468 (13.1%)
Total	421 (11.8%)	3161 (88.2%)	3582 (100%)
POC biomarkers¶			
Positive	349 (9.7%)	1391 (38.8%)	1740 (48.6%)
Negative	72 (2.0%)†	1770 (49.4%)	1842 (51.4%)
Total	421 (11.8%)	3161 (88.2%)	3582 (100%)
ECG and POC biomarkers 			
Positive	374 (10.4%)	1803 (50.3%)	2177 (60.7%)
Negative	47 (1.3%)†	1358 (37.9%)	1405 (39.2%)
Total	421 (11.8%)	3161 (88.2%)	3582 (100%)
ADP**			
Positive	418 (11.7%)	2812 (78.5%)	3230 (90.2%)
Negative	3 (0.08%)†	349 (9.7%)	352 (9.8%)
Total	421 (11.8%)	3161 (88.2%)	3582 (100%)

MACE=major adverse cardiac event. ECG=electrocardiograph. TIMI=Thrombolysis In Myocardial Infarction score for unstable angina or non-ST-elevation myocardial infarction. POC=point of care. ADP=accelerated diagnostic protocol. *ECG alone; any new ischaemia was positive. †Numbers of patients who were identified as low risk by the diagnostic parameter(s) but had a MACE (ie, false-negative cases). ‡TIMI score of ≥1 was positive and TIMI score of 0 was negative. §ECG and TIMI used. Result was positive if TIMI score was ≥1 or ECG was positive. ¶POC biomarkers: troponin I, creatine kinase MB and change, and myoglobin and change. Any positive parameter created a positive result. ||ECG and POC biomarkers used. Any positive parameter created a positive result. **ADP was negative if TIMI score was 0 and if ECG and POC biomarkers were all negative. If TIMI score was ≥1 or any other parameter was positive, then ADP was positive.

Table 3: Occurrence of MACE during initial hospital attendance or 30-day follow-up according to results of individual and combinations of the ADP test parameters

syndromes, an adjudicated diagnosis of acute myocardial infarction was made.

The predefined ADP under investigation was a combination of TIMI risk score of 0, no new ischaemic changes on the initial ECG, and normal point-of-care biomarker panel (at 0–2 h after arrival). All parameters had to be negative for the ADP to be considered negative (and thus for the patient to be identified as low risk). The TIMI score (panel 1) for unstable angina or non-ST-elevation myocardial infarction had to be zero for the sum of its seven parameters.¹⁴

New ECG ischaemic changes, with evidence that these changes were not pre-existing on previous ECGs, had to be absent. They were defined as ST-segment depression of at least 0.05 mV in two or more contiguous leads (including reciprocal changes), T-wave inversion of at

See Online for webappendix




Figure 2: Occurrence of a major adverse cardiac event during initial hospital attendance or 30-day follow-up in patients with negative results for individual and combinations of diagnostic parameters

Figures refer to numbers of patients. TIMI=Thrombolysis In Myocardial Infarction. ECG=electrocardiograph.

least 0.1 mV, or Q-waves greater than 30 ms in width and 0.1 mV or greater in depth in at least two contiguous leads.^{17,18,20} Patients with abnormal ECG findings (eg, pacing, left ventricular hypertrophy, and left bundle branch block) that were proven to be pre-existing on previous ECGs were defined as low risk.

Index test point-of-care biomarkers were measured with whole blood drawn at presentation and 2 h afterwards. Blood was immediately tested for troponin I, creatine kinase MB, and myoglobin. Results were available (to research staff only) within 15 min with the TRIAGE platform or CardioProfiler assay panels (both Alere, San Diego, CA, USA). The following assay results were predefined to be positive on either blood draw: troponin I 0.05 µg/L or greater, creatine kinase MB 4.3 µg/L or greater, or an increase of 1.6 µg/L or more within 2 h; and myoglobin concentration of 108 µg/L or greater or an increase of 25% or more within 2 h. The point cutoffs were based on manufacturer recommendations, with an elevated troponin defined as any detectable concentration of troponin. The levels of change were based on a previous publication²¹ and peer-group consensus.

Statistical analysis

Data were collected with the web-based Open-Clinica data capture system. Baseline characteristics of the study population were analysed with conventional group descriptive statistics. χ^2 analyses were used to generate two-by-two tables for the calculation of sensitivity, specificity, and positive and negative predictive values. All analyses were done with SPSS (version 18.0.0).

	ECG*	POC biomarkers†	TIMI‡	POC biomarkers and ECG§	TIMI and ECG¶	ADP
Sensitivity	35.2% (30.7–39.8)	82.9% (79.0–86.2)	96.7% (94.5–98.0)	88.8% (85.5–91.5)	98.1% (96.3–99.0)	99.3% (97.9–99.8)
Negative predictive value	89.3% (88.0–90.4)	96.1% (95.0–96.9)	97.5% (95.8–98.6)	96.7% (95.5–97.5)	98.3% (96.5–99.2)	99.1% (97.3–99.8)
Specificity	72.2% (70.6–73.7)	56.0% (54.3–57.7)	17.6% (16.3–18.9)	43.0% (41.2–44.7)	14.6% (13.4–15.8)	11.0% (10.0–12.2)
Positive predictive value	14.4% (12.3–16.7)	20.1% (18.2–22.0)	13.5% (12.3–14.8)	17.2% (15.6–18.8)	13.3% (12.1–14.5)	12.9% (11.8–14.5)
Negative likelihood ratio	0.9 (0.8–1.0)	0.3 (0.3–0.4)	0.2 (0.1–0.3)	0.3 (0.2–0.3)	0.1 (0.1–0.3)	0.1 (0.0–0.2)
Positive likelihood ratio	1.3 (1.1–1.5)	1.9 (1.8–2.0)	1.2 (1.1–1.2)	1.6 (1.5–1.6)	1.1 (1.1–1.2)	1.1 (1.1–1.3)

POC=point of care. ECG=electrocardiograph. ADP=accelerated diagnostic protocol. MACE=major adverse cardiac event. TIMI=Thrombolysis In Myocardial Infarction score for unstable angina or non-ST-elevation myocardial infarction. *ECG alone; any new ischaemia was positive. †POC biomarkers: troponin I, creatine kinase MB and change, and myoglobin and change. Any positive parameter created a positive result. ‡TIMI score of ≥ 1 was positive and TIMI score of 0 was negative. §POC biomarkers and ECG used. Any positive parameter created a positive result. ¶TIMI and ECG used. Result was positive if TIMI score was ≥ 1 or ECG was positive. ||ADP was negative if TIMI score was 0 and if ECG and POC biomarkers were all negative. If TIMI score was ≥ 1 or any other parameter was positive, then ADP was positive.

Table 4: Accuracy (95% CI) of POC biomarkers, ECG, and ADP for prediction of MACE

The trial is registered with the Australia-New Zealand Clinical Trials Registry, number ACTRN12609000283279.

Role of the funding source

The sponsors of this study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

3651 consenting eligible patients were enrolled, of whom 3582 completed 30-day follow-up (figure 1). Web-appendix p 3 shows the countries and hospitals that recruited patients. Study participants were mostly older men, either white or Chinese, and commonly had cardiovascular risk factors and background cardiovascular past medical history (table 1). A major adverse cardiac event occurred within 30 days in 421 (11.8%) patients. Non-ST-segment acute myocardial infarction (NSTEMI) was the most frequently occurring major adverse cardiac event (table 2).

The ADP identified 9.8% (352/3582) of patients as being at low risk of a major adverse cardiac event within 30 days (all ADP parameters were negative). Three (0.9%) of these patients had an event during initial hospital attendance and follow-up (figure 1). Web-appendix p 4 outlines the clinical details of these false negatives.

The combinations of parameters of the ADP were more effective at identifying patients who had a major adverse cardiac event than were the individual parameters themselves (table 3). The combination of the biomarkers and ECG without the TIMI score did not identify

47 patients with a major adverse cardiac event at day 30. With use of the ADP including TIMI score, 44 additional patients were correctly identified, which reduced the number of false negatives to three (figure 2).

Table 4 shows the statistical analysis of the ADP and its parameters for the prediction of a major adverse cardiac event by day 30. The ADP had a very high sensitivity and negative predictive value (table 4).

Secondary analysis showed that patients identified as low risk by negative ADP were associated with a median initial hospital attendance of 26·0 h (IQR 9·9–37·0) and a mean of 43·2 h (95% CI 36·2–51·2), representing 1–2 hospital bed-days.

Discussion

Findings from this large, multinational study have prospectively validated that a 2-h accelerated diagnostic protocol, with use of point-of-care biomarkers, ECG, and TIMI score, can safely identify patients at very low short-term risk of a major adverse cardiac event (panel 2). These patients could potentially be discharged several hours earlier to outpatient follow-up and further investigations than with present practices.

The near 10% possible reduction in patients needing prolonged assessment in this large patient group could reduce overcrowding in hospitals and emergency departments and provide earlier reassurance and greater convenience for patients. The potential reduction in initial length of stay accords with the findings of a six centre study in the UK.²² These findings together with those from countries included in our study represent 42% of the world's population. Extrapolation is difficult, but on the basis of incidence rates of chest pain in the USA of 2·21%, there might be 64 million presentations of chest pain per year across these study nations. If the true incidence was half of this rate, then earlier discharge of 10% of patients could affect 3·2 million presentations. Patients in this study who were identified as low risk had an initial hospital attendance of about 1–2 days; these patients could potentially be discharged within 3–4 h of arrival if follow-up investigations could be arranged as an outpatient. Increasing demand for acute hospital beds is a key challenge for modern health services.

The study shows that each of the components of the ADP is essential when used within such an early timeframe after presentation (figure 2, table 3). The use of the TIMI score within the ADP resulted in a lower and more acceptable false negative rate than when only biomarkers and ECG were used for the prediction of 30-day major adverse cardiac event (0·7% vs 11·2%).

Troponin assays with lower and more reliable levels of detection have been developed since this study started, but the assay we used was effective in this ADP. The focus of this study was the safety of the ADP when used as a whole; any contemporary troponin could be used either via the central laboratory or point of care as part

Panel 2: Research in context

Systematic review

We searched Medline from March, 1995, to December, 2010, for full reports of original research and review articles with the terms “acute coronary syndrome”, “chest pain”, “emergency department”, “risk stratification tools”, “point of care”, and “clinical decision rule”. We identified 114 articles. Abstracts were downloaded for all titles of potential relevance. Full papers were downloaded when the abstract was also deemed relevant. To be included in the final analysis, studies had to be prospective, have a large population, and have clearly described their methods and results. The methodology must have allowed the conclusions to be generalised to the emergency department population.

Interpretation

Together, the results of these studies show that the identification of patients at low risk for major adverse cardiac events is challenging. Increasing research is emerging into the use of accelerated diagnostic protocols (ADP). These protocols typically include the use of a risk stratification method, serial biomarkers, and electrocardiographs, and usually require an assessment period of 6–12 h. The results of our study indicate that a new ADP incorporating a risk stratification method (TIMI score), electrocardiograph, and point-of-care biomarker testing can identify patients at low risk of 30-day major cardiac event at 2 h.

of the ADP. Newer assays, which typically have lower detection limits and higher analytical precision, would probably improve the sensitivity of this ADP for the prediction of a major adverse cardiac event. These newer assays might be used with decision rules under development²³ for use in a broad risk population. In this trial, combinations of biomarkers provided cumulative improvement in sensitivity, but a cardiac troponin as a sole biomarker was sufficient alone to produce a high sensitivity of 98·6% (415/421) once ECG and TIMI were added. Although not an a-priori hypothesis, this finding suggests that the ADP might be optimised to include only the cardiac troponin results in conjunction with the ECG and TIMI risk score in the future. Other biomarkers (eg, copeptin and heart fatty acid binding protein) might improve the diagnostic accuracy for acute myocardial infarction; however, their use as part of an ADP has not been reported.^{24,25}

The ADP might be expanded to a broader subset by development of a more specific risk score. The TIMI score was developed from a relatively high-risk population with acute coronary syndromes, but it has been externally validated in more general emergency department populations.^{2,3,26} A modified TIMI risk score has been derived and validated in an emergency department population previously with laboratory-based troponins,^{27,28} with a sensitivity of 96·6% reported in the validation

study. There is no universally accepted definition of a low-risk patient for acute coronary syndromes. This lack of consensus is a serious concern, because according to Bayesian decision making, interpretation of post-test probability after a particular test result is dependent on knowledge of the pre-test probability. The use of a structured and reproducible method is important.^{29–33} Subjective pre-test probability estimation has much lower inter-rater agreement between clinicians than do structured methods.³⁴ Furthermore, patients presenting to an emergency department are often initially assessed by junior staff, and evidence shows that traditionally taught clinical variables and risk factors are poor predictors of acute coronary syndromes in an undifferentiated population in these clinics.^{35–37}

Patients without chest pain but who presented with atypical symptoms (fatigue, nausea, vomiting, diaphoresis, faintness, and back pain) were not included in this trial, and we were unable to quantify the number of patients presenting with these symptoms. Thus the applicability of the ADP is limited to the selected cohort of patients with chest pain (or discomfort) suggestive of acute coronary syndromes for whom the attending physician planned to investigate for these syndromes. Another limitation of this study is that this was an observational, not an intervention study. Ideally, a management study of the diagnostic protocol would now occur; however, in practice, such studies are rare.

The low specificity (11%) of our approach might be regarded as a limitation, but the ADP was used as an exclusion method to predict safety of early discharge of patients and not to establish inpatient management. These patients would otherwise have had extended observation or admission. The low specificity accords with other diagnostic instruments to exclude acute coronary syndromes.¹⁰ The goal of a more specific test is to rule-in a diagnosis if positive with sufficient certainty to initiate a change in management. In the setting that we studied, a positive protocol result merely classified patients as requiring management as usual. The optimum balance between specificity and sensitivity is difficult to define. A process yielding a higher specificity is likely to discharge a larger number of patients; however, we believe that the main focus should be on safety and therefore sensitivity. Future research should focus on methods to identify a greater proportion of patients who can be discharged earlier without significant adverse events.

Contributors

MT had overall responsibility for the trial. MT, LC, CMR, SA, DFF, SHL, WAP, and AMR contributed to the study design. MT, SA, and PMG (New Zealand); LC, WAP, and DFF (Australia); HFH and HFK (Hong Kong); RRK and MB (India); SS (Indonesia); DH, RD, and QH (China); KS-M (Korea); SHL (Singapore); PS and RS-L (Thailand); and T-FC, K-CT, F-YC, W-KC, and W-HC (Taiwan) collected data. MT, LC, CMR, SA, WAP, and MWA analysed data. MT, LC, CMR, MWA, WFP, and AMR wrote the report, which was reviewed by all authors. MT and LC did the literature search.

Conflicts of interest

MT, MB, SHL, RRK, and LC received grants and supplies by Alere Medical. MT, AMR, and LC received honoraria for previous speaking and lecturing from Alere Medical. MT, MB, AMR, SHL, RRK, LC, and W-KC received support for travel to meetings from Alere Medical. MT received provision of administrative support funds from Alere Medical. HFH and HFK received grants from Science International Corporation. HFH received support for travel from Science International Corporation. MWA received unrelated grants from HRCNZ. LC received grants from the Queensland Emergency research Foundation (QEMRF). SA received grants from the National Heart Foundation of New Zealand, and support for travel to meetings from the Christchurch Cardio-Endocrine Research Group. CMR received grants from the National Health and Medical Research Council. WAP has received grants from the QEMRF. He is a board member of Sanofi-Aventis, is a consultant for Hospira, and has been paid to give lectures for Sanofi-Aventis and Roche, all unrelated to this project. WFP has received consultancy payments from Alere for unrelated projects. SS received grants, support for travel to meetings, and fees for participation in review activities from Medquest Jaya Global. DH, RD, QH, KS-M, DFF, RS-L, SS, and PS received support from Alere to travel to meetings. T-FC, K-CT, F-YC, and W-HC received grants for nurses and support for travel from Progressive Group (Taiwan). PMG has received unrelated grants from the Health Research Council New Zealand, National Heart Foundation New Zealand, and National Health and Medical Research Council; and unrelated honoraria from Roche, AstraZenica, and Abbott Laboratories.

Acknowledgments

We thank the patients who participated in the trial; Angela Brennan, Carl Costoloe, and Philippa Loane for independent third party oversight of the study and source data verification at the Centre for Clinical Research Excellence, Monash University, Melbourne; Queensland Emergency Medicine Research Foundation and National Health and Medical Research Council (Australia), Christchurch Cardio-Endocrine Research Group (New Zealand), Alere Medical (all countries), Medquest Jaya Global (Indonesia), Science International (Hong Kong), Bio Laboratories Pte (Singapore), National Heart Foundation of New Zealand, and Progressive Group (Taiwan) for helping to subsidise the costs of the research infrastructure at study sites; Allan S Jaffe, Jeffrey A Kline, Sarah Lord, Deborah Diercks, Steven Goodacre, Anthony F T Brown, Fred Apple, and Alan Maisel for reviewing the manuscript; Naresh Trehan for administrative support and patient recruitment in India; Rahul Mehrotra for patient recruitment and data collection and verification in India; Darren M Beam for assistance with the data dictionary; Christopher M A Frampton for initial statistical advice; and Joanne M Deely for medical writing and editing.

References

- 1 Goodacre S, Cross E, Arnold J, Angelini K, Capewell S, Nicholl J. The health care burden of acute chest pain. *Heart* 2005; **91**: 229–30.
- 2 Pollack CV Jr, Sites FD, Shofer FS, Sease KL, Hollander JE. Application of the TIMI risk score for unstable angina and non-ST elevation acute coronary syndrome to an unselected emergency department chest pain population. *Acad Emerg Med* 2006; **13**: 13–18.
- 3 Chase M, Robey JL, Zogby KE, Sease KL, Shofer FS, Hollander JE. Prospective validation of the Thrombolysis in Myocardial Infarction risk score in the emergency department chest pain population. *Ann Emerg Med* 2006; **48**: 252–59.
- 4 Hollander JE. The continuing search to identify the very-low-risk chest pain patient. *Acad Emerg Med* 1999; **6**: 979–81.
- 5 Pollack CV Jr, Antman EM, Hollander JE. 2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice. *Ann Emerg Med* 2008 **52**: 344–55 e1.
- 6 Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. *Circulation* 2010; **122**: 1756–76.
- 7 Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. *Circulation* 2007; **116**: 2634–53.

- 8 Aroney CN, Dunlevie HL, Bett JHN. Use of an accelerated chest pain assessment protocol in patients at intermediate risk of adverse cardiac events. *Med J Aust* 2003; **178**: 370–74.
- 9 Bernstein SL, Aronsky D, Duseja R, et al. The effect of emergency department crowding on clinically oriented outcomes. *Acad Emerg Med* 2009; **16**: 1–10.
- 10 Steurer J, Held U, Schmid D, Ruckstuhl J, Bachmann LM. Clinical value of diagnostic instruments for ruling out acute coronary syndrome in patients with chest pain: a systematic review. *Emerg Med J* 2010; **27**: 896–902.
- 11 Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing for risk stratification in chest pain units: the chest pain evaluation by creatine kinase-MB, myoglobin, and troponin (CHECKMATE) study. *Circulation* 2001; **103**: 1832–37.
- 12 Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. *Circulation* 2007; **115**: e352–55.
- 13 Conway Morris A, Caesar D, Gray S, Gray A. TIMI risk score accurately risk stratifies patients with undifferentiated chest pain presenting to an emergency department. *Heart* 2006; **92**: 1333–34.
- 14 Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. *JAMA* 2000; **284**: 835–42.
- 15 Miller CD, Lindsell CJ, Anantharaman V, et al. Performance of a population-based cardiac risk stratification tool in Asian patients with chest pain. *Acad Emerg Med* 2005; **12**: 423–30.
- 16 Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. *Circulation* 2003; **108**: 2543–49.
- 17 Cullen L, Than M, Brown AF, et al. Comprehensive standardized data definitions for acute coronary syndrome research in emergency departments in Australasia. *Emerg Med Australas* 2010; **22**: 35–55.
- 18 Hollander JE, Blomkalns AL, Brogan GX, et al. Standardized reporting guidelines for studies evaluating risk stratification of ED patients with potential acute coronary syndromes. *Acad Emerg Med* 2004; **11**: 1331–40.
- 19 Forest RS, Shofer FS, Sease KL, Hollander JE. Assessment of the standardized reporting guidelines ECG classification system: the presenting ECG predicts 30-day outcomes. *Ann Emerg Med* 2004; **44**: 206–12.
- 20 Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). *J Am Coll Cardiol* 2001; **38**: 2114–30.
- 21 Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Serial creatinine kinase (CK) MB testing during the emergency department evaluation of chest pain: utility of a 2-hour deltaCK-MB of +1.6ng/ml. *Am Heart J* 1998; **136**: 237–44.
- 22 Goodacre SW, Bradburn M, Cross E, et al. The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. *Heart* 2011; **97**: 190–96.
- 23 Hess EP, Wells GA, Jaffe A, Stiell IG. A study to derive a clinical decision rule for triage of emergency department patients with chest pain: design and methodology. *BMC Emerg Med* 2008; **8**: 3.
- 24 Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. *J Am Coll Cardiol* 2009; **54**: 60–68.
- 25 Valle HA, Riesgo LG, Bel MS, et al. Clinical assessment of heart-type fatty acid binding protein in early diagnosis of acute coronary syndrome. *Eur J Emerg Med* 2008; **15**: 140–44.
- 26 Campbell CF, Chang AM, Sease KL, et al. Combining Thrombolysis in Myocardial Infarction risk score and clear-cut alternative diagnosis for chest pain risk stratification. *Am J Emerg Med* 2009; **27**: 37–42.
- 27 Body R, Carley S, McDowell G, et al. Can a modified thrombolysis in myocardial infarction risk score outperform the original for risk stratifying emergency department patients with chest pain? *Emerg Med J* 2009; **26**: 95–99.
- 28 Hess EP, Perry JJ, Calder LA, et al. Prospective validation of a modified thrombolysis in myocardial infarction risk score in emergency department patients with chest pain and possible acute coronary syndrome. *Acad Emerg Med* 2010; **17**: 368–75.
- 29 Dolan JG, Bordley DR, Mushlin AI. An evaluation of clinicians' subjective prior probability estimates. *Med Decis Making* 1986; **6**: 216–23.
- 30 Kassirer JP, Kopelman RI. Cognitive errors in diagnosis: instantiation, classification, and consequences. *Am J Med* 1989; **86**: 433–41.
- 31 Cahan A, Gilon D, Manor O, Paltiel O. Probabilistic reasoning and clinical decision-making: do doctors overestimate diagnostic probabilities? *QJM* 2003; **96**: 763–69.
- 32 Attia JR, Nair BR, Sibbritt DW, et al. Generating pre-test probabilities: a neglected area in clinical decision making. *Med J Aust* 2004; **180**: 449–54.
- 33 Phelps MA, Levitt MA. Pretest probability estimates: a pitfall to the clinical utility of evidence-based medicine? *Acad Emerg Med* 2004; **11**: 692–94.
- 34 Iles S, Hodges AM, Darley JR, et al. Clinical experience and pre-test probability scores in the diagnosis of pulmonary embolism. *QJM* 2003; **96**: 211–15.
- 35 Goodacre S, Locker T, Morris F, Campbell S. How useful are clinical features in the diagnosis of acute, undifferentiated chest pain? *Acad Emerg Med* 2002; **9**: 203–08.
- 36 Body R, Carley S, Wibberley C, McDowell G, Ferguson J, Mackway-Jones K. The value of symptoms and signs in the emergent diagnosis of acute coronary syndromes. *Resuscitation* 2010; **81**: 281–86.
- 37 Han JH, Lindsell CJ, Storrow AB, et al. The role of cardiac risk factor burden in diagnosing acute coronary syndromes in the emergency department setting. *Ann Emerg Med* 2007; **49**: 145–52.